You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies

Authors

  • Nurudeen A Adegoke Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Tuba N Gide Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Yizhe Mao Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Camelia Quek Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Ellis Patrick Centre for Cancer Research, Westmead Institute for Medical Research, Westmead, New South Wales, AustraliaSchool of Mathematics and Statistics, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Matteo S Carlino Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaWestmead and Blacktown Hospitals, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Serigne N Lo Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Alexander Maxwell Menzies Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaRoyal North Shore and Mater Hospitals, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Ines Pires da Silva Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaWestmead and Blacktown Hospitals, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Ismael A Vergara Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Georgina Long Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaRoyal North Shore and Mater Hospitals, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Richard A Scolyer Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaDepartment of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • James S Wilmott Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles

Citation

Adegoke NA, Gide TN, Mao Y, et al
Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
Journal for ImmunoTherapy of Cancer 2023;11:e007144. doi: 10.1136/jitc-2023-007144
Online issue publication 
October 21, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.